Valuation Genmab A/S Nasdaq

Stocks

Market Closed - Nasdaq Other stock markets 23:00:00 12/06/2026 +03			5-day change	1st Jan Change
25.08 ^USD	-0.63%		-0.28%	-18.57%

06-11	Genmab Says Subgroup Data for Follicular Lymphoma Treatment Shows 'Sustained' Efficacy Benefits	MT
06-11	Genmab A/S Presents EPCORE FL-1 Subgroup Data Demonstrating Consistent Efficacy And Safety Results For Epcoritamab In Combination With Rituximab And Lenalidomide R2 Across Relapsed Or Refractory Follicular Lymphoma Patients	CI

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	172,063	192,229	140,770	94,810	124,862	99,396	-	-
Change	-	11.72%	-26.77%	-32.65%	31.7%	-20.4%	-	-
Enterprise Value (EV) ¹	152,725	169,905	112,635	73,709	114,029	118,889	111,869	100,039
Change	-	11.25%	-33.71%	-34.56%	54.7%	4.26%	-5.9%	-10.57%
P/E Ratio	57.8x	35.2x	32.6x	12.3x	20.9x	21.4x	14.9x	9.85x
PBR	7.82x	7.07x	4.5x	2.68x	3.47x	2.44x	2.09x	1.73x
PEG	-	0.4x	-1.5x	0.1x	-1x	-1x	0.3x	0.2x
Capitalization / Revenue	20.3x	13.2x	8.54x	4.4x	5.31x	3.6x	3.07x	2.54x
EV / Revenue	18x	11.6x	6.84x	3.42x	4.85x	4.3x	3.45x	2.55x
EV / EBITDA	46.8x	25.3x	20.1x	10.4x	15.9x	14.2x	9.87x	6.15x
EV / EBIT	50.6x	26.7x	21.2x	10.5x	17x	15.9x	11.7x	7.26x
EV / FCF	77.3x	47.3x	16.1x	9.72x	15.7x	19.3x	12x	6.45x
FCF Yield	1.29%	2.12%	6.23%	10.3%	6.36%	5.18%	8.36%	15.5%
Dividend per Share ²	-	-	-	-	-	-	-	-
Rate of return	-	-	-	-	-	-	-	-
EPS ²	45.54	83.65	66.02	121.4	97.08	75.51	108.5	164.4
Distribution rate	-	-	-	-	-	-	-	-
Net sales ¹	8,482	14,595	16,474	21,526	23,497	27,645	32,414	39,181
EBITDA ¹	3,266	6,719	5,616	7,116	7,175	8,356	11,330	16,269
EBIT ¹	3,018	6,357	5,321	7,003	6,727	7,498	9,584	13,775
Net income ¹	3,008	5,522	4,352	7,844	6,083	4,712	7,019	10,551
Net Debt ¹	-19,338	-22,324	-28,135	-21,101	-10,833	19,493	12,473	643.5
Reference price ²	2,630.00	2,941.00	2,155.00	1,492.50	2,027.00	1,619.00	1,619.00	1,619.00
Nbr of stocks (in thousands)	65,423	65,362	65,322	63,524	61,599	61,393	-	-
Announcement Date	2/16/22 A	2/22/23 A	2/14/24 A	2/12/25 A	2/17/26 A	-	-	-

¹DKK in Million²DKK

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
ARGENX SE	33.17x	8.64x	26.13x	0.05%	56.42B
WUXI APPTEC CO., LTD.	16.69x	5.03x	10.91x	1.8%	44.54B
BIONTECH SE	-17.8x	4.17x	-7.3x	-.--%	22.9B
INSMED INCORPORATED	-36.36x	12.23x	-35.67x	-.--%	21.21B
WUXI BIOLOGICS (CAYMAN) INC.	20.25x	3.95x	10.26x	-.--%	16.4B
EXELIXIS, INC.	16.8x	4.85x	11.36x	-.--%	13.35B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-433.48x	29.5x	-3289.39x	-.--%	12.36B
PHARMAESSENTIA CORPORATION	36.9x	14.16x	41.61x	0.18%	11.15B
MADRIGAL PHARMACEUTICALS, INC.	-69.99x	7.06x	-63.29x	-.--%	11.08B
Average	-48.20x	9.96x	-366.15x	0.23%	23.27B
Weighted average by Cap.	-17.80x	8.58x	-188.74x	0.41%